Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes

Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S30-2. doi: 10.1086/319373.

Abstract

Macrolides are currently used to treat Streptococcus pyogenes infections where allergy or resistance prevents the use of penicillin. However, growing macrolide resistance is now seen worldwide, with rates of 5%-40% being reported. In this context it is therefore important to have other therapeutic options. The aim of this study was to ascertain the potential role of moxifloxacin, a third-generation fluoroquinolone, in the treatment of infections caused by group A S. pyogenes. The antimicrobial susceptibilities of S. pyogenes isolated from 197 adult patients with pharyngotonsillitis were analyzed by the E-test. Twelve percent of the isolates were resistant to macrolides, and 5% showed diminished susceptibility toward penicillin; none of the strains were resistant to cefotaxime or to moxifloxacin (90% minimum inhibitory concentration, 0.25 microg/mL). Therefore, moxifloxacin may be a therapeutic option in the management of S. pyogenes infections when penicillin cannot be used or when macrolide resistance may be a local issue. Clinical studies of moxifloxacin in pharyngotonsillitis are warranted.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents / pharmacology*
  • Aza Compounds*
  • Azithromycin / pharmacology
  • Clarithromycin / pharmacology
  • Drug Resistance, Microbial
  • Fluoroquinolones*
  • Humans
  • Lactams / pharmacology
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Quinolines*
  • Streptococcus pyogenes / drug effects*
  • Streptococcus pyogenes / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Lactams
  • Quinolines
  • Azithromycin
  • Clarithromycin
  • Moxifloxacin